Erasca reports FY2024 net loss $161.7M; cash $440.5M; pipeline on track for 2025 IND filings

Erasca, Inc.

Net loss for FY2024 $161.7M ($0.69/sh) vs $125.0M ($0.83/sh) in 2023.
Cash, equivalents & marketable securities $440.5M at Dec 31, 2024, up from $322.0M; runway extended to H2 2027.
R&D expenses $115.4M (excl. $22.5M in-process R&D) vs $103.8M; G&A $41.7M vs $37.7M.
IND filings expected mid-Q2 2025 for pan-RAS glue ERAS-0015 and Q2 2025 for pan-KRAS inhibitor ERAS-4001.
Phase 3 SEACRAFT-2 (naporafenib+trametinib) Stage 1 random data H2 2025; FDA FTD in NRASm melanoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.